Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Current Opinion in Molecular Therapeutics|July 26, 2002
The promise of toxicogenomicsJeffrey F Waring, Donald N HalbertCurrent Opinion in Drug Discovery & Development|February 1, 2006
The state-of-the-art in predictive toxicogenomicsMark R Fielden, Kyle L KolajaExpert Opinion on Drug Safety|March 8, 2008
The role of early in vivo toxicity testing in drug discovery toxicologyMark R Fielden, Kyle L KolajaToxicological Sciences : an Official Journal of the Society of Toxicology|June 15, 2007
A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicalsMark R Fielden, Richard Brennan, Jeremy GollubPharmacogenomics|October 24, 2006
Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix databaseBrigitte Ganter, Ronald D Snyder, Donald N Halbert, et al.Regulatory Toxicology and Pharmacology : RTP|June 17, 2014
Evaluation of genotoxicity testing of FDA approved large molecule therapeuticsSatin G Sawant, Mark R Fielden, Kurt A BlackEnvironmental and Molecular Mutagenesis|February 21, 2020
Biomarkers of genome instability in normal mammalian genomes following drug-induced replication stressSheroy Minocherhomji, Yang Liu, Yudong D He, et al.American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|June 15, 2005
Preclinical drug safety analysis by chemogenomic profiling in the liverMark R Fielden, Cecelia Pearson, Richard Brennan, et al.Proceedings of the National Academy of Sciences of the United States of America|May 15, 2003
Specificity of short interfering RNA determined through gene expression signaturesDimitri Semizarov, Leigh Frost, Aparna Sarthy, et al.Pageof 4